Jazz Pharmaceuticals (JAZZ) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 68.4% versus a gain of 11.8%. Over five years, MDGL leads with a +466.0% price change compared with +64.3% for JAZZ. Jazz Pharmaceuticals is the larger company by market cap ($15.01 billion vs $11.27 billion), about 1.3 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +4.9%).
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.9x vs 50.7x for Madrigal Pharmaceuticals). Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAZZ | MDGL |
|---|---|---|
| Share price | $231.19 | $487.72 |
| Market cap | $15.01B | $11.27B |
| 1-day change | -0.09% | -1.76% |
| YTD return | +35.99% | -16.25% |
| 1-year return | +68.36% | +11.79% |
| 5-year return | +64.31% | +466.00% |
| P/E ratio (TTM) | 15.85 | — |
| Forward P/E | 8.93 | 50.67 |
| EPS (TTM) | $14.59 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.27B | $958.40M |
| Revenue growth (YoY) | +4.88% | +432.05% |
| Net income (latest FY) | $-356.15M | $-288.28M |
| Operating margin | -10.08% | -31.31% |
| Net margin | -8.35% | -30.08% |
| 52-week high | $266.38 | $615.00 |
| 52-week low | $128.80 | $393.61 |
| Distance from 52-week high | -13.21% | -20.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +27.38% | +39.86% |
| Average volume | 850.55K | 289.31K |
| Shares outstanding | 64.91M | 23.10M |
| Employees | 2,890 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed MDGL by 56.6 percentage points over the past year.
- Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +4.88%).
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
JAZZ vs MDGL FAQ
Which is bigger, Jazz Pharmaceuticals or Madrigal Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $15.01B compared with $11.27B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, JAZZ or MDGL?
JAZZ returned +68.36% over the past 12 months, compared with +11.79% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Jazz Pharmaceuticals and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.